β2-adrenoreceptor medications and risk of Parkinson disease
- 1 November 2018
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 84 (5), 683-693
- https://doi.org/10.1002/ana.25341
Abstract
Objective Methods A recent study observed a 2-fold greater risk of Parkinson disease (PD) in relation to the beta 2-adrenoreceptor antagonist propranolol and a markedly lower risk of PD for the beta 2-adrenoreceptor agonist salbutamol. We examined whether confounding by clinical indication for these medications, that is, tremor and smoking-related pulmonary conditions, explained these associations. In a large, population-based case-control study of United States Medicare beneficiaries in 2009 with diagnosis codes, procedure codes, and prescription data (48,295 incident PD cases, 52,324 controls), we examined the risk of PD in relation to use of selected beta antagonists (propranolol, carvedilol, metoprolol), the beta 2 agonist salbutamol, and other medications used for the same clinical indications (primidone, inhaled corticosteroids). We adjusted for demographics, smoking, and overall use of medical care. We then examined the effect of also adjusting for clinical indication and applying medication exposure lagging. Results Interpretation Propranolol appeared to increase PD risk (odds ratio [OR] = 3.62, 95% confidence interval [CI] = 3.31-3.96). When we adjusted for tremor or abnormal involuntary movement prior to the PD diagnosis/reference date and lagged propranolol exposure, the association was 0.97 (95% CI = 0.80-1.18). Primidone, also used for tremor, was similarly sensitive to this adjustment and lagging. beta Antagonists not indicated for tremor appeared to reduce PD risk (carvedilol: OR = 0.77, 95% CI = 0.73-0.81; metoprolol: OR = 0.94, 95% CI = 0.91-0.97) and were insensitive to adjustment for indications and lagging. Neither salbutamol nor inhaled corticosteroids were consistently associated with PD risk. beta 2-adrenoreceptor agonists and antagonists do not appear to alter PD risk. Ann Neurol 2018;84:691-701Funding Information
- Michael J. Fox Foundation
- National Institute of Environmental Health Sciences (K24 ES017765)
- National Institute of Neurological Disorders and Stroke (R01 NS099129)
- American Parkinson Disease Association
This publication has 20 references indexed in Scilit:
- Traumatic brain injury in the prodromal period of Parkinson's disease: A large epidemiological study using medicare dataAnnals of Neurology, 2017
- β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s diseaseScience, 2017
- Controlling for Informed Presence Bias Due to the Number of Health Encounters in an Electronic Health RecordAmerican Journal of Epidemiology, 2016
- Time to First Cigarette, a Proxy of Nicotine Dependence, Increases the Risk of Pulmonary Impairment, Independently of Current and Lifetime Smoking BehaviorNicotine & Tobacco Research, 2016
- Measuring drug exposure: concordance between defined daily dose and days' supply depended on drug classJournal of Clinical Epidemiology, 2015
- Evidence-based guideline update: Treatment of essential tremorNeurology, 2011
- Asthma and cigarette smoking in a representative sample of adultsJournal of Health Psychology, 2011
- Pooled Analysis of Tobacco Use and Risk of Parkinson DiseaseArchives of Neurology, 2007
- Cigarette smoking and the incidence of Parkinson's disease in two prospective studiesAnnals of Neurology, 2001
- Metoprolol Compared With Propranolol in the Treatment of Essential TremorArchives of Neurology, 1984